Definium Therapeutics (DFTX) awards RSUs and stock options to director Krebs

Rhea-AI Filing Summary

Definium Therapeutics director Andreas Krebs received new equity awards. He was granted 4,666 restricted stock units, each representing one common share, and a stock option covering 19,188 common shares at an exercise price of $24.11 per share. Following the award, he directly holds 19,773 common shares, and the option vests in 12 equal monthly installments, with both the RSUs and option subject to possible acceleration immediately before the next annual meeting if it occurs within one year of grant and he continues in service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Krebs Andreas

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	19,188	$0.00	--
Grant/Award	Common Shares	4,666	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 19,188 shares (Direct, null); Common Shares — 19,773 shares (Direct, null)

Footnotes (1)

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date. The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

RSU grant: 4,666 units Stock option grant size: 19,188 shares Option exercise price: $24.11/share +3 more

6 metrics

RSU grant 4,666 units Each RSU equals one common share

Stock option grant size 19,188 shares Underlying common shares for new option

Option exercise price $24.11/share Exercise price for 19,188-share option

Shares held after grant 19,773 shares Common shares directly held post-transaction

RSU/option vesting schedule 1/12 monthly Both RSUs and option vest in 12 monthly installments

Option expiration June 10, 2036 Expiration date of stock option

Key Terms

restricted stock units, Stock Option (Right to Buy), vest, annual meeting, +1 more

5 terms

restricted stock units financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares"

vest financial

"The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting financial

"if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

exercise price financial

"conversion_or_exercise_price": "24.1100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/15/2026 - 04:30 PM Accepted by SEC EDGAR 06/15/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krebs Andreas

(Last) (First) (Middle)

C/O DEFINIUM THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, SUITE 8500

(Street)

NEW YORK NEW YORK 10007

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Definium Therapeutics, Inc. [ DFTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/11/2026		A		4,666(1)	A	$0	19,773	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$24.11	06/11/2026		A		19,188		(2)	06/10/2036	Common Shares	19,188	$0	19,188	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.

2. The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Mark Sullivan, Attorney-in-Fact for Andreas Krebs	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Definium Therapeutics (DFTX) report for Andreas Krebs?

Definium Therapeutics reported that director Andreas Krebs received equity compensation, including 4,666 restricted stock units and a stock option for 19,188 common shares. These awards were granted at no cash cost to him and are tied to continued board service.

How many Definium Therapeutics (DFTX) common shares does Andreas Krebs hold after this filing?

After the reported grant, Andreas Krebs directly holds 19,773 Definium Therapeutics common shares. This figure reflects his position following the award of 4,666 restricted stock units, which each represent a contingent right to receive one additional common share upon vesting.

What are the terms of the new stock option granted to Andreas Krebs at Definium Therapeutics (DFTX)?

The stock option covers 19,188 common shares at an exercise price of $24.11 per share. It vests as to one-twelfth of the underlying shares on each monthly anniversary of the grant date, with potential accelerated vesting immediately before the next annual meeting under stated conditions.

How do the restricted stock units for Andreas Krebs at Definium Therapeutics (DFTX) vest?

The 4,666 restricted stock units vest in twelve equal monthly installments starting from the grant date. If the company’s next annual meeting occurs within one year, any remaining unvested units vest immediately before that meeting, assuming he remains in service through the applicable vesting date.

Are the recent Definium Therapeutics (DFTX) insider transactions open-market purchases or sales?

The transactions are equity awards, not open-market trades. Andreas Krebs received restricted stock units and a stock option as compensation, both recorded with code A for grant or award acquisition, so no shares were bought or sold on the open market in this filing.